SCHEMBL2885708

SCHEMBL2885708

CCOC(=O)c1sc(-c2ccc(Cl)cc2)nc1C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.78
MAPT P10636 4/20 0.78
CDC7 O00311 3/20 0.73
DBF4 Q9UBU7 3/20 0.73
RAB9A P51151 4/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
NPC1 O15118 3/20 0.68
KDM4E B2RXH2 2/20 0.68
POLB P06746 1/20 0.68
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
ALDH1A1 P00352 3/20 0.65
GAA P10253 2/20 0.65
PTPN11 Q06124 2/20 0.64
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892889 0.89 CDC7 (0.77) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL28295570 0.88 SMN1; SMN2 (0.63) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL15048955 0.88 TRPM8 (1.00) TRPM8MAPTCDC7DBF4KDM4E
SCHEMBL8867692 0.88 XDH (0.74) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL290384 0.87 CDC7 (0.75) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL4274888 0.86 MAPT (0.60) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL2823339 0.86 CDC7 (0.73) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL4464882 0.86 CDC7 (0.73) TRPM8MAPTCDC7DBF4RAB9A
SCHEMBL2885887 0.86 TRPM8 (0.78) TRPM8MAPTCDC7DBF4RAB9A
Hydrochloric Acid SCHEMBL28885517 0.86 CDC7 (0.73) TRPM8MAPTCDC7DBF4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
CN-109810071-A A kind of miRNA biosynthesis inhibitor 中国科学院成都生物研究所 2019-05-28 CN disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 EP disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 WO disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed
US-20060052384-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia GLAXO GROUP LIMITED (GB) 2006-03-09 US disclosed
EP-1539158-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2005-06-15 EP disclosed
WO-2004007493-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed
WO-2004006922-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 TRPM8 3537/4885MAPT 2196/4885CDC7 261/4885
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS TRPM8 2262/4885MAPT 4575/4885CDC7 816/4885
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 TRPM8 3499/4885MAPT 2965/4885CDC7 2482/4885
US-20060052384-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia LDLR, NR1H2, NR1H3 TRPM8 719/4885MAPT 3892/4885CDC7 3840/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 TRPM8 3537/4885MAPT 2196/4885CDC7 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.